Oruka Therapeutics Management
Management criteria checks 0/4
Oruka Therapeutics' CEO is Lawrence Klein, appointed in Feb 2024, has a tenure of less than a year. directly owns 2.44% of the company’s shares, worth $11.91M. The average tenure of the management team and the board of directors is 0.6 years and 0.9 years respectively.
Key information
Lawrence Klein
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 2.4% |
| Management average tenure | less than a year |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO
Lawrence Klein (42 yo)
less than a year
Tenure
Dr. Lawrence Otto Klein, Ph D., served as Partner of Versant Venture Management, LLC since joining from 2023 to February 2024. He served as an Independent Director at Dyne Therapeutics, Inc. since Septembe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | no data | 2.44% $ 11.9m | |
| Senior Vice President of Finance & Treasurer | less than a year | no data | no data | |
| Senior Vice President of Operations & Boston Site Head | no data | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| General Counsel & Secretary | less than a year | no data | no data | |
| Vice President of Corporate Development & Strategy | no data | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| VP and Head of Chemistry | no data | no data | no data | |
| Senior Vice President of Nonclinical Research & Development | no data | no data | no data |
0.6yrs
Average Tenure
49yo
Average Age
Experienced Management: ORKA's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | no data | 2.44% $ 11.9m | |
| Independent Director | less than a year | no data | no data | |
| Independent Chairman of Board | less than a year | no data | no data | |
| Independent Director | less than a year | no data | 0.24% $ 1.2m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data |
0.9yrs
Average Tenure
40.5yo
Average Age
Experienced Board: ORKA's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/16 13:37 |
| End of Day Share Price | 2025/01/16 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oruka Therapeutics, Inc. is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitchell Kapoor | H.C. Wainwright & Co. |
| Michael Yee | Jefferies LLC |
| David Risinger | Leerink Partners LLC |